Senzime: Unique patient-oriented monitoring systems




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Senzime: Unique patient-oriented monitoring systems
Released on: October 11, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery.
  • Summary
  • Participants
  • Company
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. Lena Söderström, CEO of Senzime dicusses with PharmaVentures, Adrian Dawkes, the portfolio of technologies including bedside systems that enable automated and continuous monitoring of life-critical substances.
Mrs Lena Söderström is the CEO of Senzime. Lena has over 25 years' experience in management positions in international pharmaceutical companies and in the medical device industry. Her broad range of experience includes positions e.g. people management, project management, business development, international marketing and manufacturing. She serves as board member of Uppsala universitet Holding AB (UUAB), SLU Holding AB and Pharmacolog (publ) and is a member of the Chamber Council at Stockholm Chamber of Commerce. Lena has her BSc in Medical Science from Uppsala University, Sweden, and her second degree is an Executive MBA from the same university.
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. We are building a new global leader in the field of patient monitoring Senzime develops unique medical devices that make it possible to monitor patients' biochemical and physiological processes before, during and after an operation. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and reduce health care costs. During the second quarter of 2016, Senzime AB acquired Acacia BV, a medical device company that has developed a novel and reliable method of monitoring the depth of neuromuscular block and determine the adequacy of neuromuscular recovery during general anesthesia. The method of monitoring is designed to reduce perioperative complications in surgical patients. The merger between Senzime and Acacia creates a company with a broader market offering of patient monitoring systems of biological and physiological processes in perioperative surgical patients. The new company significantly increases Senzime’s market potential and opportunities, and benefits from Acacia’s existing international clinical network. Senzime AB shall deliver products to the healthcare market that contribute to improved patient safety and reduce health care costs. This is Senzime’s vision, and in 2015 and 2016, we have taken major steps forward, including the strategic acquisition of the company that developed OnZurf Probe, and most recently, Acacia monitoring company. The acquisitions are fully aligned with our strategy to build a global leader in patient monitoring. Through the merger, Senzime has expanded its international reach, as well as its range of medical devices designed to improve perioperative patient monitoring. As previously announced, Acacia signed a letter of intent with one of the world's premiere developers of anesthesia monitoring devices during spring 2016. Acacia received an initial smaller down payment under this agreement, in which the rest of the amounts are reported in Senzime’s results during the second quarter. The goal is to finalize a more comprehensive license during the latter part of 2016. During the second quarter or 2016, and as previously reported, we received a competitive research grant from Uppsala Bio, BIOX, to conduct a clinical study designed to clinically evaluate OnZurf Probe and CliniSenz Analyzer. We have already conducted a clinical study that monitored the blood glucose levels in patients at risk for diabetes. The next steps will be to document the benefits of OnZurf Probe and CliniSenz Analyzer in patients with esophageal cancer, which is a large and growing patient population, and we will continue to seek partnerships to help us document the clinical benefits of our products. We remain confident that we have highly attractive monitoring products and that we are capturing the perioperative market at the appropriate time. We have competitive solutions in a large and growing medical market; we will shortly introduce our products to the market, which of course is very exciting after all the years of development. As I wrote in the Q1 report, we look forward to a continually eventful 2016 and beyond.